Prostate Cancer
MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.
September 17, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
September 17, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
September 16, 2024
Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction.
September 16, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistance.
September 16, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma.
September 16, 2024
Targeted Prostate Biopsy: How, When, and Why? A Systematic Review.
September 16, 2024
Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.
September 14, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.
September 14, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.
September 14, 2024
SECuRE Trial Advances: No Dose Limiting Toxicities and Strong Preliminary Efficacy Data in First Multi-Dose Cohort
September 13, 2024